RT Journal Article
SR Electronic
T1 Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.29.20199711
DO 10.1101/2020.09.29.20199711
A1 Scott Wilkinson
A1 Huihui Ye
A1 Fatima Karzai
A1 Stephanie A. Harmon
A1 Nicholas T. Terrigino
A1 David J. VanderWeele
A1 John R. Bright
A1 Rayann Atway
A1 Shana Y. Trostel
A1 Nicole V. Carrabba
A1 Nichelle C. Whitlock
A1 Stephanie M. Walker
A1 Rosina T. Lis
A1 Houssein A. Sater
A1 Brian J. Capaldo
A1 Ravi A. Madan
A1 James L. Gulley
A1 Guinevere Chun
A1 Maria J. Merino
A1 Peter A. Pinto
A1 Daniela C. Salles
A1 Harsimar B. Kaur
A1 Tamara L. Lotan
A1 David J. Venzon
A1 Peter L. Choyke
A1 Baris Turkbey
A1 William L. Dahut
A1 Adam G. Sowalsky
YR 2020
UL http://medrxiv.org/content/early/2020/09/30/2020.09.29.20199711.abstract
AB Localized prostate cancer is distinctively characterized by intratumoral heterogeneity, and tumors with more complex evolutionary paths display more aggressive characteristics. In clinical trials of intense neoadjuvant androgen deprivation therapy (inADT), patients with complete or near-complete responses experience durable remissions. However, the molecular characteristics distinguishing exceptional responders and nonresponders at baseline have not been established. Here, we present the integrated histologic and genomic analysis of pre-treatment baseline tissue from our recent Phase 2 clinical study of inADT. Multiregion sampling demonstrated that patients with incomplete and nonresponding tumors demonstrate greater tumor diversity as estimated by phylogenetic tree reconstruction from DNA sequencing and automated analysis of immunohistochemical stains. Development of a four-factor binary model to predict poor response correlated with increased genomic diversity in our 37-patient cohort and a validation cohort of 188 Gleason score 8-10 prostate cancers. Together, these findings demonstrate that even in the primary setting, more highly evolved tumors have increased fitness to resist therapy.Competing Interest StatementH.Y. and R.T.L. perform consulting in an advisory role for Janssen Pharmaceuticals. The remaining authors declare no conflicts of interest.Clinical TrialNCT02430480Funding StatementThis work was supported by the Prostate Cancer Foundation (Young Investigator Awards to S.W., S.H., F.K., D.J.Va., R.A.M., H.Y. and A.G.S.), the Department of Defense Prostate Cancer Research Program (W81XWH-19-1-0712 to S.W., W81XWH-16-1-0433 to A.G.S.), the National Cancer Institute (HHSN261200800001E) and the Intramural Research Program of the NIH, National Cancer Institute.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This trial was approved by the Institutional Review Board of the Center for Cancer Research, National Cancer Institute (ClinicalTrials.gov identifier: NCT02430480). This study has been conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with the International Council on Harmonization guidelines on Good Clinical Practice, all applicable laws and regulatory requirements, and all conditions required by a regulatory authority and/or institutional review board. Written informed consent was obtained for all 39 patients prior to performing study-related procedures in accordance with federal and institutional guidelines.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesRaw sequencing data has been deposited in the Database of Genotypes and Phenotypes (dbGaP) accession number phs001938.v2.p1.